MedTrace Logo

A Study of OKI-179 in Patients With Solid Tumors

NCT03931681 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2021-12-06

No results posted yet for this study

Summary

This study is a Phase 1, single center, open-label study, assessing single agent dose escalation of OKI-179.

Conditions

Interventions

DRUG

OKI-179

OKI-179 single agent

Sponsors & Collaborators

  • University of Colorado, Denver

    collaborator OTHER

  • OnKure, Inc.

    lead INDUSTRY

Principal Investigators

  • Jennifer Diamond, MD · University of Colorado, Denver

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-08
Primary Completion
2021-11-27
Completion
2021-11-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03931681 on ClinicalTrials.gov